(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/238934 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 14/725* (2006.01)
C07K 14/00 (2006.01) *A61K 39/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/029973

(22) International Filing Date:
17 May 2024 (17.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/467,514 18 May 2023 (18.05.2023) US
63/574,249 03 April 2024 (03.04.2024) US

(71) Applicant: **CLADE THERAPEUTICS, INC.** [US/US]; 201 Brookline Avenue, Suite 1002, Boston, Massachusetts 02215 (US).

(72) Inventor: **ZHANG, Shuqi**; c/o Clade Therapeutics, Inc., 201 Brookline Avenue, Suite 1002, Boston, Massachusetts 02215 (US).

(74) Agent: **WEBER, Genevieve L.** et al.; 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: INHIBITING NATURAL KILLER CELL CYTOTOXICITY AGAINST CELL THERAPIES




FIG. 1

(57) Abstract: Provided herein are recombinant nucleic acids encoding one or more binding domains specific for CD300a and/or NKG2A, and vectors, engineered cells, and compositions comprising the recombinant nucleic acids. Also provided are methods of using the recombinant nucleic acids to enhance persistence of an engineered cell, such as by protecting against natural killer (NK) cell mediated killing of the engineered cell, methods of producing an engineered cell comprising the recombinant nucleic acids, and methods of treating a subject and/or improving a clinical outcome in a subject using the engineered cells.

WO 2024/238934 A1